Hispanic Broadcasting

Hispanic Broadcasting Newswire

Comprehensive Real-Time News Feed for Hispanic Broadcasting.

Results 1 - 20 of 272 in Hispanic Broadcasting

  1. LifeCare Flexible Intravenous Solutions by Hospira, Inc. Recalled:...Read the original story w/Photo

    5 hrs ago | PRWeb

    On October 15, the FDA announced that certain lots of LifeCare Flexible Intravenous Solutions by Hospira, Inc. are recalled due to potential for leakage. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers.

    Comment?

  2. Omeros suspends its Huntington's clinical trial with OMS824Read the original story

    Tuesday Oct 7 | Theflyonthewall.com

    American Academy of Ophthalmology to hold annual meeting AAO Annual Meeting 2014 is being held in Chicago on October 18-21. Omeros, Hospira enter into commercial suply agreement for Omidria Omeros Corporation said in a filing that on October 3, it, Hospira S.p.A. and Hospira Worldwide, Inc. entered into a Commercial Supply Agreement, pursuant to which Hospira will act as a non-exclusive supplier of Omeros' product Omidria for commercial sale in the United States and the European Union.

    Comment?

  3. German fund pressured to sell Mylan stake over drug used in executions, FT saysRead the original story

    22 hrs ago | Theflyonthewall.com

    International Continence Society to hold annual meeting ICS Annual Meeting 2014 is being held in Rio de Janeiro, Brazil on October 20-24. Hospira recalling one lot of Vancomycin Hydrochloride The FDA announced that Hospira is initiating a voluntary nationwide user-level recall of one lot of Vancomycin Hydrochloride.

    Comment?

  4. American Academy of Ophthalmology to hold annual meetingRead the original story

    22 hrs ago | Theflyonthewall.com

    Omeros, Hospira enter into commercial suply agreement for Omidria Omeros Corporation said in a filing that on October 3, it, Hospira S.p.A. and Hospira Worldwide, Inc. entered into a Commercial Supply Agreement, pursuant to which Hospira will act as a non-exclusive supplier of Omeros' product Omidria for commercial sale in the United States and the European Union. Pursuant to the Supply Agreement, Hospira has agreed to manufacture and supply, and Omeros has agreed to purchase, a minimum percentage of Omeros' requirements of Omidria for commercial sales and clinical supplies for the development of additional therapeutic indications in the United States.

    Comment?

  5. Hospira, Inc. v. BurwellRead the original story w/Photo

    Yesterday | JD Supra

    Case Name: Hospira, Inc. v. Burwell , Civ. No. 14-02662-GJH, U.S. Dist. LEXIS 123972 Drug Product and Patent -in-Suit: Precedex ; U.S. Patent No.

    Comment?

  6. Fresenius, others explore bid for Danone medical nutrition unit, Reuters saysRead the original story

    Tuesday Oct 7 | Theflyonthewall.com

    Danone says not carrying out review on Mead Johnson takeover, Reuters says In response to reports on Friday that French food company Danone was pursuing a takeover of pediatric nutrition company Mead Johnson , Danone made a statement on Sunday saying that it was not carrying out a review of a Mead Johnson takeover, says Reuters. Reference Link Danone reports Q3 like-for-like sales up 6.9% to EU 5.42B Danone confirmed its 2014 targets of sale growth between 4.5%-5.5%, trading operating margin stable within a range of down 20bps and up 20bps and free cash-flow of around EU 1.5B excluding exceptional items.

    Comment?

  7. Hospira Announces Voluntary Nationwide Recall Of One Lot Of 1%...Read the original story

    Friday Oct 17 | US Food and Drug Administration

    October 16, 2014 - LAKE FOREST, Ill., - Hospira, Inc. , announced today it will initiate a voluntary recall of one lot of 1% Lidocaine HCI for Injection, USP, 10 mg per mL, 30 mL Single-dose, Preservative-Free to the user level due to a confirmed customer report of particulate in a single unit. Hospira has identified the particulate as a human hair, embedded in and attached to a pinched area of the stopper.

    Comment?

  8. Hospira Given Average Recommendation of "Hold" by AnalystsRead the original story

    Thursday Oct 16 | AmericanBankingNews.com

    Hospira has earned an average rating of "Hold" from the ten ratings firms that are presently covering the stock, Analyst RN reports . One analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and one has given a buy recommendation to the company.

    Comment?

  9. LifeCare Flexible Intravenous Solutions by Hospira, Inc.: Recall - Potential for LeakageRead the original story w/Photo

    Tuesday Oct 14 | Drugs.com

    ISSUE: Hospira, Inc. announced the voluntary recall of certain lots of several products in its LifeCare line of flexible intravenous solutions due to the potential for leakage. The issue was identified during re-inspection of a manufactured product lot in which a single puncture mark was identified going through the overwrap and primary container.

    Comment?

  10. Shire tanks with AbbVie calling board meeting over mergerRead the original story

    Wednesday Oct 15 | Theflyonthewall.com

    AstraZeneca confirms AHA, ACC updated guideline AstraZeneca confirmed that the American Heart Association and American College of Cardiology have updated the guideline for the management of patients with non-ST-elevation acute coronary syndromes. The guideline supports differentiation among currently available P2Y12 inhibitors, including ticagrelor, clopidogrel, and prasugrel, for these patients.

    Comment?

  11. Danone reports Q3 like-for-like sales up 6.9% to EU 5.42BRead the original story

    Friday Oct 3 | Theflyonthewall.com

    Danone reports Q3 like-for-like sales up 6.9% to EU 5.42B Danone confirmed its 2014 targets of sale growth between 4.5%-5.5%, trading operating margin stable within a range of down 20bps and up 20bps and free cash-flow of around EU 1.5B excluding exceptional items. Fresenius in advanced talks to buy Danone medical nutrition business, FT reports Fresenius is in advanced talks to buy Danone's medical nutrition division, sources tell the Financial Times.

    Comment?

  12. Select to View Firm Press ReleaseRead the original story

    Tuesday Oct 14 | US Food and Drug Administration

    October 14, 2014 - Hospira, Inc. , today announced the voluntary recall of certain lots of several products in its LifeCare line of flexible intravenous solutions due to the potential for leakage. The issue, which Hospira notified customers about in a Dear Health Care Provider letter issued earlier this year, was identified during re-inspection of a manufactured product lot in which a single puncture mark was identified going through the overwrap and primary container.

    Comment?

  13. Vancomycin Hydrochloride for Injection USP by Hospira Recalled:...Read the original story w/Photo

    Tuesday Oct 14 | PRWeb

    On October 8, the FDA announced that one lot of Vancomycin Hydrochloride for Injection, USP, by Hospira Inc., is recalled due to uncontrolled storage during transit. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers.

    Comment?

  14. Impax to acquire Tower Holdings, Lineage Therapeutics for $700M cashRead the original story

    Thursday Oct 9 | Theflyonthewall.com

    Mylan rallies after raising Q3, FY14 profit outlook Shares of generic pharmaceutical maker Mylan are advancing after the company raised its profit outlook for the third quarter and fiscal 2014. WHAT'S NEW: This morning, Mylan raised its Q3 adjusted EPS view to $1.12-$1.16 from 90c-95c, far above the consensus of 94c.

    Comment?

  15. BioTime, Inc. Closes $31 Million FinancingRead the original story

    Thursday Oct 9 | Freshnews

    BioTime, Inc. today announced that it has closed the equity financing it disclosed on October 3, 2014, through which BioTime received $29,425,961 and certain subsidiaries received approximately $1,558,905 from the sale of BioTime common shares. BioTime and the subsidiaries intend to use the net proceeds from their sales to finance clinical trials of products under development, to finance their research and development programs, and for general working capital.

    Comment?

  16. Hospira Issues a Voluntary Nationwide Recall of One Lot of Vancomycin ...Read the original story

    Wednesday Oct 8 | US Food and Drug Administration

    FDA posts press releases and other notices of recalls and market withdrawals from the firms involved as a service to consumers, the media, and other interested parties. FDA does not endorse either the product or the company.

    Comment?

  17. Vancomycin Hydrochloride for Injection USP, Equivalent to 1 Gram...Read the original story w/Photo

    Tuesday Oct 7 | Drugs.com

    Vancomycin Hydrochloride for Injection USP, Equivalent to 1 Gram Vancomycin by Hospira, Inc.: Recall - Uncontrolled Storage During Transit ISSUE : Hospira, Inc. issued a voluntary nationwide user-level recall of one lot of Vancomycin Hydrochloride for Injection, USP, Equivalent to 1 g Vancomycin , NDC 0409-6533-01, Lot 35-315-DD with expiration date of 01 NOV 2015. The product may have experienced temperature excursions during shipment to a customer and then was further distributed by the customer.

    Comment?

  18. BioTime, Inc. and Subsidiaries to Raise $31 Million Through Sales of Common SharesRead the original story

    Monday Oct 6 | Freshnews

    BioTime, Inc. today announced that it has agreed to sell up to an aggregate of 9,431,398 common shares, in a registered direct offering at an offering price of $3.12 per share. The price per share was the closing price of our common shares on the NYSE MKT on October 2, 2014, the date on which we and the investors agreed upon the purchase price.

    Comment?

  19. Hospira, Inc. To Host Conference Call For Third-Quarter 2014 ResultsRead the original story

    Monday Oct 6 | BioSpace

    A live webcast of the conference call and related material will be available on Hospira's website at www.hospirainvestor.com . Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the webcast.

    Comment?

  20. Teva simplifaction plans expected but positive, says BMO CapitalRead the original story

    Monday Sep 29 | Theflyonthewall.com

    Teva purchase of Mylan inconsistent with deal strategy, says BMO Capital After Reuters said Teva has shown interest in Mylan as an acquisition target, BMO Capital said that while "nothing can be ruled out," its meetings with Teva management make it believe a deal for Mylan would be inconsistent with the company's current strategy. BMO raised its price target on Mylan to $42 from $41, citing the company's raised guidance, but maintains its Underperform rating on the stock.

    Comment?